No article text was recorded for this version.
inter-patient pharmacokinetic variability
Version 1 of 1102 papers172 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs
- Blog: Right dose, right now: bedside, real-time, data-driven, and personalised antibiotic dosing in critically ill patients with sepsis or septic shock—a two-centre randomised clinical trial
- Blog: Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected Pseudomonas aeruginosa Infection
- Blog: Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis
- Blog: Vancomycin Dosing Regimens based on Monte Carlo Simulation for Treated Gram-positive cocci Infection in neonates: A retrospective observational study
- Blog: Right Dose Right Now: bedside data-driven personalized antibiotic dosing in severe sepsis and septic shock — rationale and design of a multicenter randomized controlled superiority trial
- Blog: Population Pharmacokinetic Modeling and Dose Optimization of Vancomycin in Chinese Patients with Augmented Renal Clearance
- Blog: Optimizing Antiviral Dosing for HSV and CMV Treatment in Immunocompromised Patients
- Blog: Population pharmacokinetics of mycophenolate mofetil in pediatric patients early after liver transplantation
- Blog: Pharmacy Compounding Quality Control and Pharmaceutical Development Strategies for Seventeen alpha Hydroxyprogesterone Caproate in Prevention of Preterm Delivery
- Blog: Clinically relevant pharmacokinetic knowledge on antibiotic dosing among intensive care professionals is insufficient: a cross-sectional study
- Blog: Why we should sample sparsely and aim for a higher target: Lessons from model‐based therapeutic drug monitoring of vancomycin in intensive care patients
- Blog: Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study
- Blog: Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: A prospective interventional study
- Blog: Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients
- Blog: UDCA May Promote COVID-19 Recovery: A Cohort Study with AI-Aided Analysis
- Blog: Tentative exploration of pharmacodynamic substances: Pharmacological effects, chemical compositions, and multi-components pharmacokinetic characteristics of ESZWD in CHF-HKYd rats
- Blog: Pharmacokinetics and predicted neutralization coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
- Blog: PK/PD study of ceftazidime/avibactam in patients with severe intra-abdominal infections treated by continuous veno–venous hemofiltration
- Blog: Population pharmacokinetics of peginterferon α2a in patients with chronic hepatitis B
- Blog: Book Review
- Blog: Tirofiban in Acute Ischemic Stroke: Mechanistic Rationale, Clinical Advances, and Emerging Therapeutic Strategies
- Blog: Clinical Outcomes of Trimethoprim/Sulfamethoxazole in Critically Ill Patients with Stenotrophomonas maltophilia Bacteremia and Pneumonia Utilizing Renal Replacement Therapies
- Blog: Cost-effectiveness of data driven personalised antibiotic dosing in critically ill patients with sepsis or septic shock
- Blog: Pharmacokinetics study of atracurium, dexmedetomidine, midazolam and 1-hydroxymidazolam in patients undergoing acute aortic dissection surgery
- Blog: Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy
- Blog: Association between anlotinib trough plasma concentration and treatment outcomes in advanced non-small-cell lung cancer
- Blog: Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease
- Blog: Anticoagulant monitoring of rivaroxaban by chromogenic anti-Xa assays and UHPLC-MS/MS in patients with atrial fibrillation
- Blog: Comparison of empirical high-dose and low-dose of meropenem in critically ill patients with sepsis and septic shock
- Blog: Cyclosporine concentration prediction using clustering and support vector regression methods
- Blog: Estimation of median effective doses and 95% effective doses of oliceridine combined with propofol for day-case hysteroscopy under total intravenous anesthesia with preserved spontaneous breathing: an up-and-down sequential allocation trial
- Blog: Exploration of clinical breakpoint of Danofloxacin for <i>Glaesserella parasuis</i> in plasma and in PELF
- Blog: Right Dose, Right Now: Development of AutoKinetics for Real Time Model Informed Precision Antibiotic Dosing Decision Support at the Bedside of Critically Ill Patients
- Blog: AI-Driven Tacrolimus Dosing in Transplant Care: Cohort Study
- Blog: Concentration monitoring and dose optimization for infliximab in Crohn’s disease patients: a machine learning-based covariate ensemble model
- Blog: Paclitaxel drives TREM2+ macrophage expansion underlying its inferior therapeutic efficacy compared to Nab-paclitaxel
- Blog: Reinforcement Learning for Adaptive Tacrolimus Dosing with Drug-Drug Interaction Management
- Blog: Respiratory failure due to novel 2009 pandemic A/H1N1 influenza in a chronic hemodialysis patient
- Blog: Multi-site infection by methicillin-resistant Staphylococcus aureus in a six-year old girl: a case report
- Blog: Evaluation the Effect of Methotrexate on Psoriasis Based on Specialized Pharmaceutical Education
- Blog: The pharmacokinetics, pharmacodynamics and tolerability of SHR6508 in Chinese healthy subjects
- Blog: Annual Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease During Infliximab Maintenance Therapy: Balancing Efficacy with Risk of Pharmacokinetic Failure
- Blog: Exogenous lactate infusion (ELI) in traumatic brain injury: higher dose is better?
- Blog: Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study
- Blog: Glucagon-like peptide-1 receptor agonists: new strategies and therapeutic targets to treat atherosclerotic cardiovascular disease
- Blog: Exploratory Pharmacokinetics of Geniposide in Rat Model of Cerebral Ischemia Orally Administered with or without Baicalin and/or Berberine
- Blog: Global Deep Forecasting with Patient-Specific Pharmacokinetics.
- Blog: Detecting CD20-Rituximab interaction forces using AFM single-molecule force spectroscopy
- Blog: Deep reinforcement learning extracts the optimal sepsis treatment policy from treatment records
- Blog: Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes
- Blog: Machine learning-based prediction model for teicoplanin plasma concentrations in adults with liver disease using real-world data
- Blog: Noradrenaline causes a spread of association in the hippocampal cognitive map
- Blog: Safety and recommendation of voriconazole for invasive pulmonary aspergillosis in severe liver disease patients: a retrospective cohort study
- Blog: Discrepancy between perceptions and acceptance of clinical decision support Systems: implementation of artificial intelligence for vancomycin dosing
- Blog: Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients
- Blog: Pharmacokinetic and safety analysis of biosimilar adalimumab in healthy volunteers in Bangladesh
- Blog: A Model Perspective Explanation of the Long-Term Sustainability of a Fully Human BCMA-Targeting CAR (CT103A) T-Cell Immunotherapy
- Blog: Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis
- Blog: Construction and Interpretation of Prediction Model of Teicoplanin Trough Concentration via Machine Learning
Showing 60 of 102 papers.
History & citation
Current · Permanent link
- Precision Dosing for Individualized Drug Therapy merged into this direction (61% overlap)
Cite this direction
Latest version (a living page):
@misc{lacuna_inter_patient_pharmacokinetic_variabilit_573a11b6,
title = {inter-patient pharmacokinetic variability},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/inter-patient-pharmacokinetic-variability/rdr_573a11b659124e07a1670896042c16d5},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-19},
}This exact version (version 1, frozen text):
@misc{lacuna_inter_patient_pharmacokinetic_variabilit_573a11b6_v1,
title = {inter-patient pharmacokinetic variability},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/inter-patient-pharmacokinetic-variability/rdr_573a11b659124e07a1670896042c16d5/v/1},
note = {Version 1, frozen 2026-10-04. Accessed 2026-11-19},
}